Akebia Therapeutics - AKBA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 367.29%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.07
▼ -0.03 (-2.73%)

This chart shows the closing price for AKBA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Akebia Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKBA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKBA

Analyst Price Target is $5.00
▲ +367.29% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is $5.00, with a high forecast of $6.00 and a low forecast of $4.00. The average price target represents a 367.29% upside from the last price of $1.07.

This chart shows the closing price for AKBA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Akebia Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2024HC WainwrightBoost TargetBuy ➝ Buy$5.00 ➝ $6.00N/A
3/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00N/A
11/29/2023BTIG ResearchReiterated RatingBuy$4.00Low
11/17/2023HC WainwrightBoost TargetBuy ➝ Buy$3.75 ➝ $5.00Low
9/27/2023HC WainwrightReiterated RatingBuy ➝ Buy$3.75Low
8/28/2023HC WainwrightUpgradeNeutral ➝ Buy$2.00 ➝ $3.75Low
8/11/2023HC WainwrightReiterated RatingNeutral ➝ Neutral$2.00Low
5/31/2023Piper SandlerUpgradeNeutral ➝ OverweightLow
4/26/2023HC WainwrightBoost Target$1.25 ➝ $2.00Low
3/31/2023HC WainwrightReiterated RatingNeutral$1.25N/A
3/10/2023HC WainwrightReiterated RatingNeutral$1.25Low
2/22/2023HC WainwrightReiterated RatingNeutral$1.25Low
5/16/2022HC WainwrightLower Target$2.00 ➝ $1.25Medium
4/1/2022Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
3/31/2022BTIG ResearchDowngradeBuy ➝ NeutralMedium
3/31/2022Needham & Company LLCDowngradeBuy ➝ HoldHigh
3/31/2022HC WainwrightDowngradeBuy ➝ Neutral$10.00 ➝ $2.00High
3/31/2022MizuhoDowngradeBuy ➝ Neutral$6.00 ➝ $2.00High
3/30/2022Piper SandlerDowngradeOverweight ➝ Neutral$8.00 ➝ $2.00High
11/11/2021HC WainwrightBoost TargetBuy$6.00 ➝ $10.00High
3/8/2021Cantor FitzgeraldInitiated CoverageOverweight$8.00High
3/8/2021HC WainwrightLower TargetBuy$9.00 ➝ $6.00Low
1/29/2021JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
10/26/2020HC WainwrightLower TargetBuy$10.00 ➝ $9.00High
9/4/2020Morgan StanleyLower TargetEqual Weight$12.00 ➝ $3.00High
9/4/2020BTIG ResearchLower TargetBuy$26.00 ➝ $6.00Medium
9/4/2020HC WainwrightLower TargetBuy$17.00 ➝ $10.00Medium
9/4/2020MizuhoLower TargetBuy$17.00 ➝ $6.00Medium
9/3/2020JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralMedium
8/11/2020Needham & Company LLCInitiated CoverageBuy$18.00High
8/11/2020MizuhoReiterated RatingBuy$17.00High
7/15/2020Morgan StanleyBoost TargetEqual Weight$11.00 ➝ $12.00Medium
7/15/2020HC WainwrightReiterated RatingBuyHigh
6/29/2020Needham & Company LLCInitiated CoverageBuy$18.00High
5/6/2020Royal Bank of CanadaBoost TargetPositive ➝ Sector Perform$8.00 ➝ $12.00Low
5/6/2020Morgan StanleyBoost TargetEqual Weight$9.00 ➝ $11.00Low
5/6/2020JPMorgan Chase & Co.Boost TargetOverweight$13.00 ➝ $18.00Low
5/6/2020MizuhoBoost TargetBuy$15.00 ➝ $17.00Medium
5/6/2020HC WainwrightBoost TargetBuy$16.00 ➝ $17.00Medium
5/5/2020Needham & Company LLCBoost TargetBuy$15.00 ➝ $18.00High
3/19/2020MizuhoReiterated RatingBuy$15.00High
3/11/2020MizuhoLower TargetBuy$16.00 ➝ $15.00High
3/10/2020Needham & Company LLCReiterated RatingBuy$15.00High
2/20/2020JPMorgan Chase & Co.Boost TargetOverweight$10.00 ➝ $13.00High
2/19/2020HC WainwrightReiterated RatingBuy$16.00High
11/19/2019MizuhoReiterated RatingBuy$16.00Medium
11/14/2019Needham & Company LLCLower TargetBuy$18.00 ➝ $15.00Medium
9/9/2019HC WainwrightReiterated RatingBuy$17.00High
8/9/2019MizuhoSet TargetBuy$16.00N/A
8/6/2019HC WainwrightLower TargetBuy ➝ Buy$19.00 ➝ $17.00High
7/11/2019HC WainwrightReiterated RatingBuy ➝ Buy$23.00 ➝ $21.00Medium
(Data available from 5/28/2019 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/31/2023
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/30/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/30/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2024
  • 5 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/28/2024
  • 10 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/29/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/28/2024
  • 6 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
5/28/2024

Current Sentiment

  • 6 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Akebia Therapeutics logo
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.07
Low: $1.03
High: $1.12

50 Day Range

MA: $1.45
Low: $1.07
High: $2.24

52 Week Range

Now: $1.07
Low: $0.78
High: $2.48

Volume

2,842,194 shs

Average Volume

3,987,207 shs

Market Capitalization

$224.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Akebia Therapeutics?

The following Wall Street analysts have issued research reports on Akebia Therapeutics in the last twelve months: BTIG Research, HC Wainwright, Piper Sandler, and StockNews.com.
View the latest analyst ratings for AKBA.

What is the current price target for Akebia Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Akebia Therapeutics in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 367.3%. HC Wainwright has the highest price target set, predicting AKBA will reach $6.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $4.00 for Akebia Therapeutics in the next year.
View the latest price targets for AKBA.

What is the current consensus analyst rating for Akebia Therapeutics?

Akebia Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AKBA will outperform the market and that investors should add to their positions of Akebia Therapeutics.
View the latest ratings for AKBA.

What other companies compete with Akebia Therapeutics?

How do I contact Akebia Therapeutics' investor relations team?

Akebia Therapeutics' physical mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is (617) 871-2098 and its investor relations email address is [email protected]. The official website for Akebia Therapeutics is www.akebia.com. Learn More about contacing Akebia Therapeutics investor relations.